This will be a good measure of Will Dix's ability to steer and manage stakeholders. It's an opportunity to clearly differentiate himself from the progenitor company.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025